Natera
NTRA
$328.93
+0.86%
Natera, Inc. is a molecular diagnostics and bioinformatics company that develops cell-free DNA testing platforms, with flagship products including the Panorama non-invasive prenatal test (NIPT), Horizon carrier screening, Signatera molecular residual disease (MRD) monitoring for oncology, and Prospera for organ transplant rejection assessment. The company has established itself as a category-defining player in the rapidly growing MRD and liquid biopsy space, where Signatera's clinical validation and reimbursement traction position it as a potential standard of care in oncology surveillance. The current investor narrative centers on Signatera's explosive volume growth, which is driving revenue acceleration — most recently 38.8% year-over-year growth — alongside a visible path toward sustained profitability, as evidenced by the company's first positive quarterly net income in Q4 2025. However, the stock's extraordinary 89% one-year rally has raised questions about valuation sustainability, particularly given the company's still-negative trailing earnings and the recent Goldman Sachs downgrade to Neutral, even as high-profile investors like Stanley Druckenmiller have taken concentrated positions.…
NTRA
Natera
$328.93
Related headlines
Investment Opinion: Should I buy NTRA Today?
We assign a Hold rating on NTRA, balancing its exceptional growth story against a valuation that already reflects much of the optimism. The analyst consensus is Strong Buy with an average target of $344.33, implying just 4.7% upside from the current $328.93, which suggests the risk/reward is skewed to the downside in the near term. While the company's 38.8% revenue growth and dominant position in MRD are compelling, the stock's 89% one-year rally and premium multiple leave little room for error.\n\nThe supporting evidence for a constructive view includes: 1) Revenue growth of 38.8% year-over-year in Q1 2026, far exceeding the diagnostics industry average of mid-single digits; 2) Gross margin expansion to 64.8% from 63.2% a year ago, demonstrating operating leverage; 3) Positive free cash flow of $18.0 million in Q1 2026 and $92.0 million TTM, a critical inflection; and 4) A fortress balance sheet with $1.09 billion in cash and a current ratio of 3.39, funding growth without dilution. However, the PS ratio of 13.6x and EV/Sales of 17.1x are well above the industry average of 3-6x, and the forward PE of -3,196x underscores that profitability is still nascent.\n\nThe biggest risks that could invalidate the thesis are: 1) A deceleration in Signatera volume growth below 25%, which would likely compress the multiple; 2) Reimbursement headwinds or competitive pressure from Guardant Health and Exact Sciences; and 3) Continued net losses and stock-based compensation dilution. We would upgrade to Buy if the stock pulls back to the $270-$280 support zone (implying a PS of ~11x) or if Q2 2026 results show sustained positive net income and operating margin expansion. We would downgrade to Sell if revenue growth falls below 20% or if gross margin contracts below 60%. Relative to its history, the current PS of 13.6x is below the historical average but above the 2022 trough of 17.3x, suggesting the stock is fairly valued to slightly overvalued.
Sign up to view all
NTRA 12-Month Price Forecast
Natera presents a compelling growth story with Signatera driving 38.8% revenue growth and a clear path to profitability, supported by a fortress balance sheet and positive free cash flow. However, the stock's 89% one-year rally has pushed valuation multiples to premium levels (13.6x PS, 17.1x EV/Sales), and the recent Goldman Sachs downgrade highlights growing concerns about sustainability. The risk/reward is balanced: while the long-term opportunity in MRD is substantial, near-term upside to the average analyst target is limited at just 4.7%, and the high beta of 1.534 amplifies downside risk. We would upgrade to bullish if the stock pulls back to the $270-$280 support zone or if Q2 2026 results demonstrate sustained positive net income and operating margin expansion. We would downgrade to bearish if revenue growth decelerates below 25% or if gross margin contracts below 62%, signaling that the growth premium is eroding.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Natera's 12-month outlook, with a consensus price target around $344.33 and implied upside of +4.7% versus the current price.
Average Target
$344.33
0 analysts
Implied Upside
+4.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$280 - $435
Analyst target range
Natera is covered by 23 analysts, with a consensus recommendation of "Strong Buy" and a recommendation mean of 1.46 (where 1.0 is a Strong Buy and 5.0 is a Strong Sell). The average price target is $344.33, implying approximately 4.7% upside from the current price of $328.93. This consensus leans bullish, but the modest implied upside suggests that much of the near-term optimism is already priced in. The distribution of recent institutional ratings is overwhelmingly positive: Canaccord Genuity, Morgan Stanley, Evercore ISI, Guggenheim, Barclays, BTIG, and JP Morgan have all maintained Buy or Overweight ratings, with only Goldman Sachs downgrading to Neutral from Buy in June 2026. The target price range spans from a low of $280.00 to a high of $435.00, a spread of $155 (or 55% of the low target), indicating significant dispersion in analyst expectations. The high target of $435 assumes continued hyper-growth in Signatera volumes, successful expansion into new oncology indications, and a clear path to sustained profitability, potentially driven by operating leverage and reimbursement wins. The low target of $280 — roughly 15% below the current price — likely prices in margin compression from rising R&D and sales costs, competitive threats in the MRD space, or a broader market de-rating of high-multiple diagnostics stocks. The wide spread signals high uncertainty, which is typical for a high-beta, early-stage profitability story; investors should weigh the strong institutional backing against the risk that the stock has already run ahead of its fundamental support.
Bulls vs Bears: NTRA Investment Factors
The bull case rests on Natera's exceptional 38.8% revenue growth, expanding gross margins, positive free cash flow, and a fortress balance sheet that funds its dominant position in the high-growth MRD market. The bear case centers on an extreme valuation (13.6x PS, 17.1x EV/Sales) that prices in flawless execution, volatile profitability with a recent $85.1 million quarterly loss, and technical overextension after an 89% one-year rally. Currently, the bull evidence has the stronger foundation given the accelerating revenue trajectory and analyst consensus of Strong Buy, but the valuation premium and Goldman Sachs downgrade introduce meaningful caution. The single most important tension is whether Signatera's adoption curve can sustain 30%+ growth long enough to justify the premium multiple, or whether a deceleration will trigger a sharp multiple compression. Resolution of this tension—likely via upcoming reimbursement decisions and oncology data readouts—will determine whether the stock breaks above $343 or corrects toward the $270-$280 support zone.
Bullish
- Signatera drives 38.8% revenue growth: Q1 2026 revenue reached $696.6 million, up 38.8% year-over-year from $501.8 million, with sequential growth every quarter since Q2 2025. This acceleration is powered by Signatera's clinical adoption in MRD monitoring, a market with a long runway as it becomes standard of care in oncology surveillance.
- Gross margin expansion and FCF inflection: Gross margin improved to 64.8% in Q1 2026 from 63.2% a year earlier, while free cash flow turned positive at $18.0 million and TTM FCF reached $92.0 million. This demonstrates operating leverage as scale efficiencies kick in and the company approaches sustainable profitability.
- Fortress balance sheet with $1.09B cash: Natera holds $1.09 billion in cash with a current ratio of 3.39 and debt-to-equity of just 0.125, providing ample runway to fund $210.7 million in quarterly R&D and commercial expansion without dilutive financing. This significantly de-risks the growth story.
- Strong analyst consensus and Druckenmiller backing: 23 analysts rate NTRA a Strong Buy (mean 1.46), with an average target of $344.33 and high target of $435.00. Billionaire Stanley Druckenmiller's concentrated position adds high-profile validation to the institutional bull case.
Bearish
- Extreme valuation leaves no margin for error: At a PS ratio of 13.6x and EV/Sales of 17.1x, NTRA trades at a steep premium to the diagnostics industry average of 3-6x sales. The forward PE of -3,196x and PEG of 230.6 highlight that profitability remains distant relative to the price paid.
- Profitability is volatile and still negative: Q1 2026 swung to a net loss of $85.1 million (net margin -12.2%) from a $47.3 million profit in Q4 2025, which was flattered by a $60.6 million tax benefit. Operating margin remains negative at -13.4%, and stock-based compensation of $95.1 million continues to dilute shareholders.
- Goldman Sachs downgrade signals caution: Goldman Sachs downgraded NTRA to Neutral from Buy in June 2026, citing valuation concerns after the stock's parabolic run. This is a notable crack in the otherwise bullish analyst consensus and may presage further downgrades if growth decelerates.
- High beta and technical overextension: With a beta of 1.534 and a 28.2% maximum drawdown in the past year, NTRA is 53% more volatile than the market. The stock trades at 92.5% of its 52-week range, and the 6-month gain of 75.1% dwarfs the 1-month gain of 4.1%, suggesting momentum is decelerating.
NTRA Technical Analysis
Natera is in a powerful, sustained uptrend, with the stock up 89.2% over the past year and 43.7% year-to-date. At a current price of $328.93, the stock is trading at approximately 92.5% of its 52-week range (52-week low of $157.43 and high of $343.18), positioning it near the upper boundary of its annual range. This proximity to highs signals strong momentum but also raises the risk of overextension, particularly after such a steep multi-month advance. The stock's relative strength versus the S&P 500 is striking: 73.0 percentage points over one year and 31.7 percentage points year-to-date, confirming that NTRA is a clear market leader in relative terms. Short-term momentum remains positive but is decelerating relative to the longer-term trend. The 1-month change of 4.1% and 3-month change of 55.1% show that the bulk of recent gains occurred in the June-August window, with the pace moderating in September. The 1-month relative strength of 5.2 percentage points versus SPY indicates continued outperformance, though the modest 0.86% single-day gain on the most recent session suggests consolidation. Notably, the 6-month change of 75.1% dwarfs the 1-month change, implying that the stock has entered a digestion phase after a parabolic run — a pattern that often precedes either a healthy continuation or a sharper mean-reversion pullback. Key technical levels are well-defined: the 52-week high at $343.18 serves as immediate resistance, while the 52-week low at $157.43 represents major support. A breakout above $343 would likely require a fundamental catalyst (e.g., strong Signatera data or reimbursement expansion) and could open the door to new all-time highs, whereas a breakdown below the $300 psychological level could trigger a deeper correction toward the $270-$280 area, which corresponds to the July consolidation zone. With a beta of 1.534, NTRA is approximately 53% more volatile than the broader market, meaning position sizing should account for amplified drawdown risk; the maximum drawdown of -28.2% over the past year underscores this volatility, even within a strong uptrend.
Beta
1.53
1.53x market volatility
Max Drawdown
-28.2%
Largest decline past year
52-Week Range
$157-$343
Price range past year
Annual Return
+89.2%
Cumulative gain past year
| Period | NTRA Return | S&P 500 |
|---|---|---|
| 1m | +4.1% | -1.6% |
| 3m | +55.1% | +1.3% |
| 6m | +75.1% | +13.9% |
| 1y | +89.2% | +16.3% |
| ytd | +43.7% | +12.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
NTRA Fundamental Analysis
Natera's revenue trajectory is robust and accelerating, with Q1 2026 revenue of $696.6 million representing 38.8% year-over-year growth from $501.8 million in Q1 2025. The multi-quarter trend shows consistent sequential gains: revenue rose from $546.6 million in Q2 2025 to $592.2 million in Q3 2025, $665.5 million in Q4 2025, and $696.6 million in Q1 2026. The Product segment dominates at $693.9 million, while Oncology contributes a nominal $100,000 — though this segment classification likely understates Signatera's true contribution, as the test is bundled within the product line. The sustained 30%+ growth rate, driven by Signatera's clinical adoption and expanding reimbursement, supports a compelling investment case predicated on continued market penetration in the MRD space. Profitability is improving but remains uneven. Gross margin stands at 64.8% in Q1 2026, up from 63.2% in Q1 2025 and 61.8% in Q3 2024, reflecting favorable product mix and scale efficiencies. However, the company reported a net loss of $85.1 million in Q1 2026 (net margin of -12.2%), a sharp reversal from the $47.3 million profit in Q4 2025 (net margin of +7.1%). This volatility is partly attributable to a $95.1 million stock-based compensation expense in Q1 2026 and a $60.6 million tax benefit in Q4 2025 that flattered the prior quarter. Operating margin remains negative at -13.4%, though this is a marked improvement from -20.2% in Q2 2025 and -57.2% in Q1 2023, indicating a clear trajectory toward breakeven. The balance sheet is exceptionally strong, with a current ratio of 3.39, a debt-to-equity ratio of just 0.125, and $1.09 billion in cash at the end of Q1 2026. Free cash flow turned positive at $18.0 million in Q1 2026, contributing to a trailing twelve-month FCF of $92.0 million, while operating cash flow was $40.2 million. The company's cash position and low leverage provide ample runway to fund R&D ($210.7 million in Q1 2026) and commercial expansion without external financing, significantly reducing financial risk despite ongoing net losses.
Quarterly Revenue
$696644000.0B
2026-03
Revenue YoY Growth
+38.8%
YoY Comparison
Gross Margin
64.8%
Latest Quarter
Free Cash Flow
$92010000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is NTRA Overvalued?
Because Natera reported negative trailing net income (EPS of -$0.0066), the PE ratio is not meaningful; the trailing PE of -150.7x and forward PE of -3,196.3x confirm that earnings-based metrics are inapplicable. Instead, the PS ratio of 13.6x is the primary valuation metric, reflecting the market's willingness to pay a premium for high-growth diagnostics. The forward PE of -3,196x, while negative, implies that analysts expect a dramatic earnings inflection — consensus estimated EPS of $5.31 for the forward period — which, if achieved, would represent a massive swing from current losses and suggests the market is pricing in a near-term profitability breakthrough. On a peer comparison basis, Natera's PS ratio of 13.6x and EV/Sales of 17.1x are elevated relative to the broader Medical Diagnostics & Research industry, where mature players often trade at 3-6x sales. This premium is justified by Natera's 38.8% revenue growth rate, which far exceeds the industry average of mid-single-digit growth, and its dominant position in the high-growth MRD market. However, the premium also embeds significant execution risk; any slowdown in Signatera adoption or reimbursement headwinds could compress multiples sharply. Historically, Natera's PS ratio has ranged from a low of 17.3x in Q2 2022 to a high of 70.4x in Q2 2021, with the current 13.6x sitting below the historical average but above the 2022 trough. The PB ratio of 18.3x is near the upper end of its historical band (ranging from 5.6x in Q4 2022 to 33.4x in Q2 2021), suggesting that while the stock is not cheap on an asset basis, the market is pricing in substantial intangible value from its IP and pipeline. The current valuation appears to reflect optimistic growth expectations, leaving little margin for error.
PE
-150.7x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-138.1x
Enterprise Value Multiple
Investment Risk Disclosure
Natera's financial risks are primarily tied to its ongoing net losses and heavy reliance on stock-based compensation. Despite a strong balance sheet with $1.09 billion in cash and a debt-to-equity ratio of 0.125, the company reported a net loss of $85.1 million in Q1 2026, a sharp reversal from the $47.3 million profit in Q4 2025 that was boosted by a one-time $60.6 million tax benefit. Operating margin remains negative at -13.4%, and stock-based compensation of $95.1 million in Q1 2026 represents a significant non-cash expense that dilutes shareholders and masks true cash profitability. Additionally, revenue is heavily concentrated in the Product segment ($693.9 million of $696.6 million), and while Signatera is bundled within it, any slowdown in oncology test volumes or reimbursement pressure could disproportionately impact results. The company's path to sustained profitability depends on continued top-line growth and operating leverage, leaving little room for execution missteps.\n\nMarket and competitive risks are elevated given Natera's premium valuation and high beta. The stock trades at a PS ratio of 13.6x and EV/Sales of 17.1x, well above the diagnostics industry average of 3-6x, implying that any growth deceleration could trigger a severe multiple compression. With a beta of 1.534, NTRA is 53% more volatile than the broader market, making it vulnerable to macro-driven selloffs, particularly if interest rates remain elevated and compress growth stock valuations. Competitive threats in the MRD space are intensifying, with rivals such as Guardant Health and Exact Sciences investing heavily in liquid biopsy. The recent Goldman Sachs downgrade to Neutral highlights growing concerns that the stock has run ahead of fundamentals, and further downgrades could catalyze a de-rating.\n\nThe worst-case scenario for Natera would involve a combination of slowing Signatera volume growth, reimbursement setbacks, and a broader market rotation away from high-multiple healthcare stocks. In this scenario, the stock could retrace to its 52-week low of $157.43, representing a decline of approximately 52% from the current price of $328.93. Even a less severe correction to the analyst low target of $280 would imply a 15% downside. Given the maximum drawdown of -28.2% over the past year, investors should be prepared for significant volatility; a realistic adverse scenario could see the stock fall 30-40% to the $200-$230 range if growth decelerates below 25% and margins fail to improve. The high short ratio of 3.78 suggests that short sellers are already positioning for such a pullback, which could amplify downside momentum.
FAQ
The key risks of holding NTRA are ranked as follows: 1) Valuation risk — the PS ratio of 13.6x and EV/Sales of 17.1x leave no margin for error, and any growth deceleration could trigger a severe multiple compression; 2) Profitability risk — Q1 2026 net loss of $85.1 million and operating margin of -13.4% show that sustained profitability is not yet assured, and stock-based compensation of $95.1 million dilutes shareholders; 3) Competitive risk — rivals like Guardant Health and Exact Sciences are investing heavily in MRD, and any loss of Signatera's clinical edge could slow adoption; and 4) Macro risk — with a beta of 1.534, NTRA is highly sensitive to interest rate movements and sector rotation, and a risk-off environment could disproportionately impact the stock.
Our 12-month forecast for NTRA includes three scenarios: a bull case (25% probability) with a target range of $400-$435, driven by accelerated Signatera adoption and sustained profitability; a base case (55% probability) with a target range of $320-$360, assuming 30-35% revenue growth and gradual margin improvement; and a bear case (20% probability) with a target range of $250-$280, reflecting decelerating growth and competitive pressures. The base case is most likely, anchored by the analyst average target of $344.33 and the assumption that Natera maintains its growth trajectory while inching toward profitability. Key to the base case is that gross margin holds above 64% and revenue growth stays above 30%.
NTRA appears overvalued on traditional metrics, with a PS ratio of 13.6x and EV/Sales of 17.1x, well above the diagnostics industry average of 3-6x. The forward PE of -3,196x and PEG of 230.6 reflect that profitability is still nascent, and the market is pricing in a dramatic earnings inflection. Compared to its own history, the current PS of 13.6x is below the historical average but above the 2022 trough of 17.3x, suggesting a fair-to-rich valuation. The premium is justified only if Natera sustains 30%+ revenue growth and achieves durable profitability. If growth decelerates or margins disappoint, the multiple could compress sharply toward the industry average, implying significant downside. Thus, the stock is overvalued relative to peers but fairly valued relative to its own growth trajectory.
NTRA is a good buy only for investors with a high risk tolerance and a long-term horizon, given its premium valuation and volatile profitability. The stock trades at $328.93, just 4.7% below the average analyst target of $344.33, suggesting limited near-term upside. However, the company's 38.8% revenue growth, expanding gross margins, and positive free cash flow provide a strong fundamental backdrop. The biggest downside risk is a re-rating to the analyst low target of $280, implying 15% downside, or a deeper correction to the 52-week low of $157.43 in a severe scenario. For those comfortable with a beta of 1.534 and a 28.2% maximum drawdown, NTRA offers exposure to a category-defining franchise in MRD. A better entry point may emerge on a pullback to the $270-$280 support zone.
NTRA is more suitable for long-term investment (minimum 2-3 years) than short-term trading, given its high beta of 1.534, lack of dividend, and volatile earnings. The company is in a growth stage, investing heavily in R&D ($210.7 million in Q1 2026) and commercial expansion, which suppresses near-term profits but builds long-term value. Short-term traders may find opportunities in the stock's momentum, but the 28.2% maximum drawdown and 3.78 short ratio indicate elevated risk of sharp reversals. For long-term investors, the key is to monitor Signatera's adoption curve and the path to sustained profitability; a holding period of at least 2-3 years allows time for these catalysts to play out. Given the premium valuation, staggered buying on dips is prudent.